Canagliflozin: Dose & Heart Benefits
New research clarifies the critical link between canagliflozin and patient outcomes.Discover how the SGLT2 inhibitor impacts heart health, as recent findings reveal that the drug’s cardiovascular benefits are directly tied to dosage, notably for those managing type 2 diabetes. The 300mg dose demonstrates a superior ability to reduce major adverse cardiac events and all-cause mortality rates versus a placebo. Delve into these crucial insights, including a gender-based analysis of heart failure hospitalization. News Directory 3 provides a detailed look into the implications of these findings. Discover what’s next …